Bellevue Group AG trimmed its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Get Rating) by 5.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,193,200 shares of the company’s stock after selling 120,652 shares during the quarter. Axonics accounts for approximately 2.2% of Bellevue Group AG’s holdings, making the stock its 10th biggest holding. Bellevue Group AG owned approximately 4.43% of Axonics worth $154,489,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. increased its stake in Axonics by 2.9% during the third quarter. BlackRock Inc. now owns 3,504,942 shares of the company’s stock worth $246,888,000 after acquiring an additional 97,908 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Axonics in the 3rd quarter worth about $248,000. Royal Bank of Canada boosted its stake in shares of Axonics by 1,001.9% during the 3rd quarter. Royal Bank of Canada now owns 20,638 shares of the company’s stock worth $1,454,000 after purchasing an additional 18,765 shares during the period. Point72 Hong Kong Ltd grew its holdings in Axonics by 239.2% during the 3rd quarter. Point72 Hong Kong Ltd now owns 3,022 shares of the company’s stock valued at $213,000 after purchasing an additional 2,131 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its stake in Axonics by 208.2% in the third quarter. Cubist Systematic Strategies LLC now owns 171,887 shares of the company’s stock worth $12,108,000 after purchasing an additional 116,110 shares during the last quarter. Institutional investors own 97.49% of the company’s stock.
Axonics Trading Up 0.2 %
Shares of NASDAQ:AXNX traded up $0.10 on Tuesday, reaching $57.75. The company had a trading volume of 124,514 shares, compared to its average volume of 768,301. Axonics, Inc. has a 52-week low of $38.41 and a 52-week high of $79.92. The firm’s 50 day simple moving average is $62.79 and its 200-day simple moving average is $67.04.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on AXNX shares. Truist Financial decreased their price target on Axonics from $90.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, December 20th. Needham & Company LLC downgraded shares of Axonics from a “buy” rating to a “hold” rating in a research note on Monday, October 10th. Morgan Stanley dropped their price objective on Axonics from $92.00 to $76.00 and set an “overweight” rating on the stock in a research note on Friday, January 6th. Wells Fargo & Company raised their price objective on Axonics from $83.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, November 1st. Finally, Jefferies Financial Group initiated coverage on Axonics in a report on Wednesday, October 12th. They set a “hold” rating and a $75.00 price objective on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $78.11.
Insider Activity
In other news, Director Esteban Lopez sold 2,000 shares of Axonics stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $67.42, for a total value of $134,840.00. Following the transaction, the director now directly owns 3,600 shares in the company, valued at approximately $242,712. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Esteban Lopez sold 2,000 shares of Axonics stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $67.42, for a total value of $134,840.00. Following the transaction, the director now directly owns 3,600 shares in the company, valued at approximately $242,712. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Rinda Sama sold 13,425 shares of the firm’s stock in a transaction on Tuesday, January 31st. The stock was sold at an average price of $61.15, for a total value of $820,938.75. Following the completion of the sale, the chief operating officer now directly owns 80,858 shares of the company’s stock, valued at approximately $4,944,466.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 169,610 shares of company stock worth $10,955,456. 2.31% of the stock is currently owned by company insiders.
About Axonics
Axonics, Inc is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women.